文献速递临床试验与 GCP基础与转化研究

肝移植术后心输出量优化(COLT)试验:可行性随机对照试验研究方案

Cardiac output Optimisation following Liver Transplant (COLT) trial: study protocol for a feasibility randomised controlled trial.
PubMed 文献 · Trials · 2018-03-07

COLT 试验为前瞻性、单中心、随机对照可行性研究,纳入活检证实肝硬化且拟行首次肝移植的 18–80 岁成人,术后即刻随机接受目标导向液体治疗(GDFT)或标准治疗并持续 12 小时。主要终点为可行性,次要终点包括安全性、移植物与患者生存、肝功能、Clavien-Dindo 分级并发症、ICU 与住院时间及生活质量。

要点

  • 肝硬化肝移植患者术后早期呈高动力循环,液体需求评估困难。
  • COLT 试验评估术后 12 小时内 GDFT 方案的可行性与安全性。
  • 主要终点为可行性,次要终点涵盖生存、并发症与住院时长等。

核心结论

  • 肝硬化肝移植患者术后 GDFT 的可行性尚不明确,COLT 试验旨在评估患者与临床医生对招募的支持度、方案依从性、退出情况及后续大试验的合适终点。

研究设计与样本

  • COLT 为前瞻性、单中心、随机对照可行性研究,纳入活检证实肝硬化、拟行首次肝移植的 18–80 岁同意成人。
  • 干预组术后即刻起接受基于每搏量优化的方案化 GDFT 并持续 12 小时,对照组接受不测量每搏量与心输出量的标准治疗;两组均用 FloTrac(EV1000)监测心输出量与每搏量,12 小时后液体管理恢复标准治疗。

关键数值与推荐

  • 主要终点为可行性;次要终点包括干预安全性评估、移植物与患者生存、肝功能、按 Clavien-Dindo 标准分级的术后并发症、ICU 与住院时间及生活质量。
  • 试验注册号 ISRCTN10329248,注册日期 2016 年 4 月 4 日。

临床怎么用

  • 若 GDFT 在该人群被证明可行且安全,则需开展多中心试验以证明其疗效与成本效果。

局限性

  • 原文指出围术期 GDFT 虽在部分外科人群可改善结局,但也检测到伤害信号;肝硬化肝移植患者心血管生理与一般外科患者明显不同。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with liver cirrhosis undergoing liver transplantation have a hyperdynamic circulation which persists into the early postoperative period making accurate assessment of fluid requirements challenging. Goal-directed fluid therapy (GDFT) has been shown to reduce morbidity and mortality in a number of surgery settings. The impact of GDFT in patients undergoing liver transplantation is unknown. A feasibility trial was designed to determine patient and clinician support for recruitment into a randomised controlled trial of GDFT following liver transplantation, adherence to a GDFT protocol, participant withdrawal, and to determine appropriate endpoints for a subsequent larger trial to evaluate the efficacy of GDFT in patients undergoing liver transplantation. METHODS: The Cardiac output Optimisation following Liver Transplant (COLT) trial is designed as a prospective, single-centre, randomised controlled study to assess the feasibility and safety of GDFT in liver transplantation for patients with cirrhosis. Consenting adults (aged between 18 and 80 years) with biopsy-proven liver cirrhosis who have been selected to undergo a first liver transplantation will be included in the trial and randomised into GDFT or standard care starting immediately after surgery and continuing for the first 12 h thereafter. Both groups will have cardiac output and stroke volume monitored using the FloTrac (EV1000) device. The intervention will consist of a protocolised GDFT approach to patient management, using stroke volume optimisation. The control group will receive standard care, without stroke volume and cardiac output measurement. After 12 h the patient's fluid management will revert to standard of care. The primary endpoint of this study is feasibility. Secondary endpoints will include a safety assessment of the intervention, graft and patient survival, liver function, postoperative complications graded by Clavien-Dindo criteria, length of intensive care and hospital stay and quality of life across the intervention and control groups. DISCUSSION: There is a growing body of evidence that the use of perioperative GDFT in surgical patients can improve outcomes; however, signals of harm have also been detected. Patients with liver cirrhosis undergoing liver transplantation have markedly different cardiovascular physiology than general surgical patients. If GDFT is proven to be feasible and safe in this patient group, then a multicentre trial to demonstrate efficacy and cost-effectiveness will be required. TRIAL REGISTRATION: International Standard Randomised Controlled Trial Registry, ID: ISRCTN10329248. Registered on 4 April 2016.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Froghi F, Koti R, Gurusamy K, et al. Cardiac output Optimisation following Liver Transplant (COLT) trial: study protocol for a feasibility randomised controlled trial. Trials. 2018. PMID: 29514697. doi:10.1186/s13063-018-2488-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。